Storyline
New insights into tumor microenvironment and immune effects in blood cancers and CAR-T therapy
Coverage centers on: cfRNA signatures predict CAR-T outcomes in LBCL.
Evidence locked
Today's free sample is only available for the edition's flagship storyline.
Evidence preview
- cfRNA signatures predict CAR-T outcomes in LBCLmedRxiv
- CAR-T secretome impairs hematopoietic stem cellsbioRxiv